United Kingdom (UK)
Recombinant monoclonal antibody to Endomucin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma v5c7.8.
UniProt Accession Number of Target Protein: Q9R0H2
Alternative Name(s) of Target: Endomucin-1/2; Mucin-14; MUC-14
Immunogen: This antibody was raised by immunizing female lewis rats with b.END.3 cells.
Specificity: This antibody is specific for carbohydrate epitopes of endomucin. The epitopes were resistant to endoglycosidase F. Endothelial sialomucin, also called endomucin or mucin-like sialoglycoprotein, which interferes with the assembly of focal adhesion complexes and inhibits interaction between cells and the extracellular matrix.
Application Notes: In an attempt to identify the antigen to which this antibody binds multiple experiments were preformed. First, immunohistochemistry was preformed on normal mouse organs using the rat version of this antibody. Further, flow cytometry was preformed on mouse cells using the rat version of this antibody. This clone was also used successfully in immunoprecipitation and the immunoprecipitated proteins were immunoblotted using the mouse version of this antibody (Morgan et al, 1999; pmid:9864158). To analyse the expression of endomucin during development of the vascular system immunohistochemistry was preformed on tissue from mouse embryos using the mouse version of this antibody (Brachtendorf et al, 2001; pmid:11747076). While characterizing antibodies against human endomucin using immunohistochemistry, the rat version of this antibody was used as a negative control (Samulowitz et al, 2002; pmid:12000719). To better understand the influence of blood flow on hematopoietic stem and progenitor cell (HSPC) homing to the bone marrow (BM) microvasculature of the calvarial bone two-photon intravital microscopy was preformed on a moiuse using the rat version of this antibody (Stewen and Bixel, 2019; pmid:31197772). The mouse version of this antibody was also used for immunohistochemistry on human pancreatic cancer cell lines to asssess antitumor activity of nintedanib (Awasthi et al, 2015; pmid:25527450). To eludicate the mechanisms behind the ability of antiangiogenic therapy to stimulate cancer cell invasion and metastasis immunohistochemistry was preformed on tumor cells from KIC transgenic mice (Aguilera et al, 2013; pmid:24346431).
Antibody first published in:
Morgan et al. Biochemical Characterization and Molecular Cloning of a Novel Endothelial-Specific Sialomucin Blood. 1999 Jan 1;93(1):165-75. PMID:9864158
Note on publication:
Rat monoclonal antibodies were generated against cell surface antigens of the mouse endothelioma cell line bEND.3.